Provided by Tiger Trade Technology Pte. Ltd.

Keros Therapeutics, Inc.

11.01
-0.5100-4.43%
Post-market: 11.010.00000.00%19:30 EDT
Volume:185.32K
Turnover:2.08M
Market Cap:218.30M
PE:-3.55
High:11.63
Open:11.56
Low:10.95
Close:11.52
52wk High:22.55
52wk Low:9.69
Shares:19.83M
Float Shares:18.25M
Volume Ratio:1.23
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1046
EPS(LYR):2.30
ROE:-17.16%
ROA:-11.78%
PB:0.83
PE(LYR):4.79

Loading ...

Sep 29, 2026

Major Issues Report

Form 8-K - Current report
Sep 28, 2026

Major Issues Report

Form 8-K - Current report
Sep 09, 2026

Major Issues Report

Form 8-K - Current report
Aug 19, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 03, 2026

Major Issues Report

Form 8-K - Current report
Aug 03, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 03, 2026

Major Issues Report

Form 8-K - Current report
Jul 30, 2026

Major Issues Report

Form 8-K - Current report
Jul 30, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Jul 22, 2026

Major Issues Report

Form 8-K - Current report
Jul 17, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Jun 25, 2026

Major Issues Report

Form 8-K - Current report
Jun 12, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 03, 2026

Major Issues Report

Form 8-K - Current report
Jun 01, 2026

Major Issues Report

Form 8-K - Current report
May 15, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
May 14, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]